Plantable Health Inc. announced the opening of a new Clinical Trial, NUTRIVENTION-3, at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York with Dr. Urvi Shah as Principal Investigator. This trial follows on the back of the promising recently presented preliminary results for NUTRIVENTION study (NCT04920084). The primary objective for this trial is to evaluate the impact of Plantable intervention on stool butyrate levels present in the gut microbiome for patients with Myeloma, Monoclonal Gammopathy of Unknown Significance (MGUS), and Smoldering Multiple Myeloma (SMM).

Secondary endpoints of this trial evaluate BMI reduction, metabolic indicators including inflammatory markers, blood sugar and insulin markers, lipid markers and quality of life. The recent White House announcement now acknowledges Food as Medicine as a fundamental pillar for the reversal of diet-related chronic disease, supporting the expansion of the health insurers (government and private) to cover Food as Medicine services along with expanded coverage for nutrition counseling coverage. Plantable's clinical trials with clinically proven results enables Plantable to pursue insurance coverage from payers, while bringing providers, such as hospital systems, a turnkey solution for the reduction of metabolic markers associated with diet- related chronic disease, including some forms of cancer.

NUTRIVENTION 3 will begin recruitment in the coming two weeks.